Aardvark Therapeutics reported cash from operations of -$17.60M and free cash flow of -$17.60M for the quarter ended Jun 2026, down 78.8% year over year. This cash flow statement covers 10 quarters of results from Mar 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | -2.07M | -5.48M | -4.09M | -8.73M | -9.29M | -14.36M | -16.35M | -17.58M | -21.57M | -14.39M |
| Share-based Compensation | 0.07M | 0.05M | 0.14M | 0.17M | 0.23M | 0.63M | 1.50M | 1.58M | 2.00M | 1.95M |
| Cash from Operations | -2.19M | -4.21M | -3.96M | -7.73M | -11.39M | -9.84M | -16.13M | -16.81M | -18.87M | -17.60M |
| Depreciation, Depletion & Amortization | ||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.00M | -0.00M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Change in Working Capital | ||||||||||
| Change in Account Payables | -0.45M | 0.63M | -0.58M | 1.19M | 0.65M | 2.58M | -0.61M | -2.37M | 2.42M | -2.41M |
| Change in Accured Expenses | 0.48M | 0.61M | 0.29M | -0.00M | 1.41M | 1.81M | 1.03M | 2.17M | -1.26M | -2.88M |
| Other Working Capital Changes | 0.33M | 0.05M | -0.25M | 0.29M | 4.36M | -0.08M | 1.31M | 0.37M | 0.33M | -0.54M |
| Investing Activities | ||||||||||
| Capital Expenditures | 0.01M | 0.09M | 0.01M | 0.01M | 0.09M | 0.00M | ||||
| Cash from Investing Activities | -0.01M | -0.09M | -0.01M | -11.89M | -112.62M | 9.41M | 29.25M | 24.30M | 34.25M | 28.75M |
| Financing Activities | ||||||||||
| Change in Capital Stock | ||||||||||
| Net Equity Issued and Repurchased | 85.00M | 91.08M | 0.00M | 0.26M | ||||||
| Misc. | ||||||||||
| Cash from Financing Activities | 82.94M | 0.06M | -1.01M | 88.88M | -0.07M | 0.17M | 0.27M | 0.00M | 0.26M | |
| Change in Cash | -2.19M | 78.63M | -3.90M | -20.64M | -35.14M | -0.51M | 13.29M | 7.77M | 15.38M | 11.41M |
| Free Cash Flow | -2.19M | -4.31M | -3.96M | -7.73M | -11.39M | -9.94M | -16.13M | -16.81M | -18.87M | -17.60M |
| Net Cash Flow | -2.19M | 78.63M | -3.90M | -20.64M | -35.14M | -0.51M | 13.29M | 7.77M | 15.38M | 11.41M |
Pull Aardvark Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=AARD&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "AARD", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=AARD&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();